Clinical trials: Pharmacotherapy
Melanoma
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination chemotherapy of investigator's choice in…
- Trial name
- NCT06008106
- Testing
- tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Advanced Gastric Cancer
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.
- Trial name
- GRANITE-1 (NCT00879333)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 122 sites in United States, Argentina and 20 more
- Volunteers
- 656 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Neoplasms
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
This is a study to evaluate the efficacy (effectiveness) and the safety of regorafenib when given in combination with chemotherapy mFOLFOX6 as first line therapy in patients with metastatic colorectal cancer (CRC).
- Trial name
- NCT01289821
- Testing
- Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 54 people
- Sponsor
- Bayer
Urinary Tract Infection
An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
The purpose of this study is to compare the effectiveness of antibiotic flomoxef with cefepime for the treatment of complicated urinary tract infections (cUTIs) in Russian adults.
- Trial name
- FLORUS (NCT02302092)
- Testing
- Flomoxef, Cefepime
- Where
- 5 sites in Russia
- Volunteers
- 13 people
- Sponsor
- Takeda
Essential Hypertension
Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
The purpose of this study is to evaluate the antihypertensive effect of azilsartan medoxomil compared with valsartan in Chinese participants with essential hypertension.
- Trial name
- NCT02480764
- Testing
- Azilsartan medoxomil, Valsartan
- Where
- 30 sites in China
- Volunteers
- 612 people
- Sponsor
- Takeda
Acute Myeloid Leukemia With FLT3/ITD Mutation
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
The purpose of this study is to determine the clinical benefit of XY0206 therapy in participants with FLT3-ITD mutated AML who are refractory to or have relapsed after prior AML therapy as shown with overall survival (OS)…
- Trial name
- NCT05876832
- Testing
- XY0206, Salvage Chemotherapy
- Volunteers
- 312 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Dose Finding Study
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants
The purpose of this study is to characterize the safety and tolerability profile of escalating dose levels of ENV8058 (TAK-058) solution when administered as a single oral dose in healthy adults.
- Trial name
- NCT02153099
- Testing
- TAK-058 (ENV8058)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Takeda
Breast Cancer
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
Phase III Clinical Trial to Compare the Efficacy and the Safety of AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Taxotere Versus AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Nanoxel M as Neoadjuvant…
- Trial name
- NCT05207514
- Testing
- Nanoxel M, Taxotere, Doxorubicin
- Where
- South Korea
- Volunteers
- 26 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Gastroesophageal-junction Cancer, Monoclonal Antibody
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with…
- Conditions
- Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT06532006
- Testing
- HLX22, Pembrolizumab, Trastuzumab
- Where
- 208 sites in United States, Argentina and 15 more
- Volunteers
- 550 people
- Sponsor
- Shanghai Henlius Biotech
Colitis, Ulcerative, Crohn Disease
A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants
The purpose of this study is to assess the PK of vedolizumab following a single intravenous infusion in healthy adult Chinese participants.
- Trial name
- NCT03329209
- Testing
- Vedolizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Takeda
Fatigue, Breast Cancer
Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy
The goal of this clinical trial is to test the effect of the administration of APPORTAL® in addition to the SoC (recommended physical exercise), in patients with breast cancer, suffering from fatigue during neoadjuvant and…
- Trial name
- NCT06137833
- Testing
- APPOPRTAL®
- Where
- 5 sites in Italy
- Volunteers
- 92 people
- Sponsor
- Pharmanutra S.p.a.
Ovarian Cancer
Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer
The purpose of this study is to determine how effective and safe a new investigational drug is in treating persistent or recurrent ovarian cancer in patients who have received a platinum/taxane based chemotherapy and whose…
- Trial name
- NCT00097409
- Testing
- Ispinesib
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Solid Tumors
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
hPV19 is a monoclonal antibody (mAb) directed against vascular endothelial growth factor (VEGF). hPV19 binds to human VEGF with unique binding site on VEGF different from that of Bevacizumab(Avastin) and inhibits the binding of…
- Trial name
- NCT03503604
- Testing
- hPV19 mAb, 5-Fluorouracil, Oxaliplatin
- Where
- China
- Volunteers
- 18 people
- Sponsor
- SuZhou Stainwei Biotech Inc.
Nonsquamous Non-small Cell Lung Cancer
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic…
- Trial name
- NCT03829319
- Testing
- Pembrolizumab, Carboplatin, Cisplatin
- Where
- 158 sites in United States, Argentina and 15 more
- Volunteers
- 761 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
This purpose of this observational study is to review medical chart and patient survey data collection within an early access to medicines scheme (EAMS) program.
- Trial name
- NCT04936399
- Testing
- Nivolumab
- Where
- 36 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- Bristol-Myers Squibb
Ovarian Cancer, Fallopian Tube Cancer
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- MRD (NCT05739981)
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Imunon
Breast Neoplasms
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants…
- Trial name
- NCT02756364
- Testing
- Fulvestrant, Sapanisertib
- Where
- 53 sites in United States, Spain
- Volunteers
- 141 people
- Sponsor
- Calithera Biosciences, Inc
Non-small Cell Lung Cancer, Solid Tumors
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
This is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in…
- Conditions
- Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
- Trial name
- TroFuse-008 (NCT06049212)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
- Where
- 7 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Venous Thromboembolism
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
- Trial name
- NCT00641732
- Testing
- TAK-442, Enoxaparin
- Where
- 64 sites in United States, Canada
- Volunteers
- 1,045 people
- Sponsor
- Takeda
Persistent, Recurrent, or Metastatic Cervical Cancer
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic…
- Trial name
- NCT05798819
- Testing
- GLS-010, paclitaxel, cisplatin
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.